

**CONVENTIONAL VERSUS THREE
DIMENSIONAL CONFORMAL RADIATION
THERAPY AND CONCURRENT
CHEMOTHERAPY FOR PATIENTS WITH
INOPERABLE, NON-SMALL CELL LUNG
CANCER**

Thesis
Submitted for partial fulfillment of the MD degree
In
Radiation Oncology and Nuclear Medicine

By
Ahmed Maamoun Abdl Hamid
M.B.B.Ch, M.Sc. of Radiation Oncology and Nuclear Medicine

Supervised By

**Prof. Dr. Salwa
Massoud Ibrahim**

Professor of Radiation Oncology and
Nuclear Medicine
Faculty of Medicine – Ain Shams
University

**Prof. Dr.
Asma Aly Hassan**

Professor of Radiation Oncology and
Nuclear Medicine
Faculty of Medicine – Cairo University

Prof. Dr. Ehab Mostafa Mohamed

Professor of Radiation Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Amin El-Sayed Ahmed Amin

Assistant Professor of Radiation Physics - Radiation Oncology and
nuclear medicine Department
Faculty of Medicine – Ain Shams University

Faculty of Medicine - Ain Shams University
2009

Acknowledgement

First and for most, thanks are due to Allah, to whom I relate any success in achieving any work in my life.

Special thanks are due to my dear staff at the Radiation Oncology Department, Washington University School of Medicine, St. Louis, MO, USA, who made it possible for this research project to come to light: **Dr. Jeffrey Bradley, MD**, Assistant Professor of Radiation Oncology and **Dr. Issam El Naqa, Ph.D**, Assistant Professor at the division of Bioinformatics and Outcome Research.

My words stand short of my supreme gratitude and thanks to **Dr. Salwa Massoud Ibrahim** (May Allah rest her sole), Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt, **Dr. Asma Aly Hassan**, Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt, **Dr. Ehab Mostafa Mohamed**, Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt, and **Dr. Amin El-Sayed Ahmed Amin**, Assistant Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt, for their honest and constant guidance to complete this work, words of thanks are so little for their great help in preparation of this work.

Finally, I wish to thank all members of my family for their continuous help, encouragement and support.

Ahmed Maamoun Nofal

LIST OF CONTENTS

Contents	i
List of abbreviations.	iii
List of tables and appendices.	vii
List of figures.	ix
Introduction and aim of the work.	1
Review of literature.	3
• Epidemiology.	3
• .Etiology.	4
• Anatomy.	6
• Pathology and natural history.	9
• Patterns of spread.	10
• Clinical presentation.	12
• Diagnostic and staging work-up.	16
• Staging.	22
• Pathological classification	24

List of contents

• Prognostic factors.	26
• Treatment.	27
Materials and methods	59
Results	79
Discussion	95
Summary and conclusion.	103
References.	105
Arabic summary.	

LIST OF ABBREVIATIONS

2D	2-dimensional.
3D	3-dimensional
3D-CRT	3-dimensional conformal radiation therapy
4D-CT	4-dimensional computed tomography.
ACR	American college of radiology.
ADL	Activity of daily living.
AG3T	Acute grade 3 toxicity.
AJCC	American joint committee on cancer.
BAC	Broncho-alveolar carcinoma.
CALGB	Cancer and leukemia group B
CCRT	Concurrent chemoradiotherapy.
CHART	Continuous hyperfractionated accelerated radiotherapy.
CR	Complete remission.
CT	Computed tomography.
CTCAE	Common terminology criteria for adverse events.
CTH	Chemotherapy.
CTV	Clinical target volume.
DM	Distant metastases.
ECOG	Eastern cooperative oncology group.

List of abbreviations

EGFR	Epidermal growth factor receptor.
ENI	Elective nodal irradiation.
EORTC	European organization for research and treatment of cancer.
FDA	Food and drug administration.
FDG	Fluorodeoxyglucose.
GTV	Gross target volume
HART	Hyperfractionated accelerated radiotherapy.
HIPPA	Health insurance probability and accountability act.
ICRU	International commission on radiation units.
IGRT	Image-guided radiotherapy.
IMRT	Intensity modulated radiotherapy
LAMP	Locally advanced multimodality protocol.
LF	Local failure.
LRC	Loco-regional control.
LRR	Loco-regional recurrence.
NCCTG	North central cancer treatment group.
NCI	National cancer institute.
NR	No response.
NSCLC	Non-small cell lung cancer.
OR	Overall response.
OS	Overall survival.

List of abbreviations

PCI	Prophylactic cranial irradiation.
PET	Positron emission tomography.
PR	Partial response.
PS	Performance status.
PTV	Planning target volume.
RT	Radiation therapy.
RTOG	Radiation therapy oncology group
SBRT	Stereotactic body radiotherapy.
SCLC	Small cell lung cancer.
SVC	Superior vena cava.
SWOG	Southwest oncology group.
TBFNA	Transbronchial fine-needle aspiration.
TGF-beta	Transforming growth factor beta
VEGF	Vascular endothelial growth factor.

LIST OF TABLES

Table 1	Sites of metastasis correlated with histologic type (at autopsy).	12
Table 2	TNM descriptors for NSCLC.	22
Table 3	Stage grouping: TNM subsets.	24
Table 4	World Health Organization Lung Cancer Classification.	25
Table 5	Treatment related grade 3 and 4 toxicities reported by Vokes et al., 2007	33
Table 6	Paclitaxel and Carboplatin dose adjustments according to degree of hematological toxicity.	69
Table 7	Paclitaxel and Carboplatin dose adjustments according to degree of neurotoxicity.	69
Table 8	Patient and tumor characteristics.	80
Table 9	Patient compliance.	82
Table 10	Acute grade 3 toxicity events (AG3T) during concurrent phase.	83
Table 11	Grade 3 toxicity events during consolidation treatment.	84
Table 12	Response rates after concurrent chemo-RT (CCRT).	85

List of Tables


Table 13	Response rates at the end of treatment.	86
Table 14	Failure sites.	88
Table 15	Sites of distant metastases (DM).	88
Table 16	Univariate analysis of factors affecting Overall Survival (OS).	91
Table 17	Cox proportional hazard model for overall survival (OS).	91

LIST OF APPENDICES

Appendix 1	ECOG/Zubrod Score Performance Status.	73
Appendix 2	ICRU 50 designations.	73
Appendix 3	RTOG/EORTC acute radiation morbidity grading criteria.	74
Appendix 4	RTOG/EORTC late radiation morbidity grading criteria.	75
Appendix 5	Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for related treatment complications.	76

LIST OF FIGURES

Figure 1	Regional nodal stations for lung cancer staging.	8
Figure 2	Primary lymphatic drainage for lung.	8
Figure 3	Lung fibrosis after thoracic radiation.	56
Figure 4	Typical four-field beam arrangement for treatment of stage III non-small lung cancer.	66
Figure 5	Locoregional control (LRC) according to treatment group.	87
Figure 6	Progression free survival (PFS) according to treatment group.	89
Figure 7	Overall survival (OS) according to treatment group.	90
Figure 8	Progression free survival (PFS) for patients who did not receive consolidation treatment and those who did.	92
Figure 9	Overall survival (OS) for patients who did not receive consolidation treatment and those who did.	93



INTRODUCTION AND AIM OF THE WORK

INTRODUCTION AND AIM OF THE WORK


Approximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC) have locally or regionally advanced disease not amenable for surgical resection. Concurrent chemoradiation is the standard of therapy for patients with unresectable locally advanced NSCLC who have a good performance status and no significant weight loss (*Govindan et al., 2008*).

Concurrent chemoradiation (chemo-RT) is the standard treatment for patients with inoperable locally advanced NSCLC (*Fournel et al., 2005*). In order to improve the outcome obtained with concurrent chemo-RT, clinical research is focusing on additional combination chemotherapy administered in the induction or consolidation setting in addition to the standard concurrent chemo-RT (*Choy et al., 2002*).

Improved radiation therapy techniques using precise targeting of the tumors have played a key role in achieving more favorable overall outcome with less toxicity in patients with locally advanced NSCLC. Moreover, it has been shown that higher than conventional doses of thoracic radiation can be administered safely in combination with chemotherapy. Omission of elective nodal irradiation (ENI) was associated with a very low incidence of isolated nodal failure (INF), and allowed for more radiation dose escalation with acceptable therapeutic ratio. The integration of functional imaging with FDG-PET for radiotherapy treatment planning is an important advance that will further mitigate the potential impact of ENI in locally advanced NSCLC. PET imaging may also refine radiotherapy target volumes by displaying the extent of “active” disease, including differentiating tumor from postobstructive atelectasis (*Govindan et al., 2008*).

Introduction and Aim of the work

This prospective study was designed to try to answer the question whether or not the advent of the 3-dimensional conformal radiation treatment (3D-CRT) made a difference as regards to more preferable outcome and less toxicity compared to the conventional 2-dimensional radiation treatment (2D-RT), when given concurrently with weekly paclitaxel/carboplatin and followed by 2 cycles of the same chemotherapeutic agents in full systemic doses, in patients with inoperable locally advanced non-small cell lung cancer. The study primary endpoints were overall survival (OS) and progression free survival (PFS). Secondary endpoints included toxicity, objective response (OR), locoregional control (LRC), pattern of failure, and isolated nodal failure (INF).



REVIEW OF LITERATURE

REVIEW OF LITERATURE

Epidemiology

Worldwide, lung cancer is the most common (1.35 million of 10.9 million new cases) and the deadliest (1.18 million of 6.7 million cancer-related deaths) form of cancer (*Ozols et al., 2007*). The United States 2006 cancer statistics showed that lung cancer is the second most common cancer for both men and women (92,700 or 13% of all cases, and 81,770 or 12% of all cases, respectively), but the number-one cancer killer in both sexes (90,330 men, 31% of all cancer-related deaths; and 72,300 women, 26% of all cancer-related deaths). In fact, more people in the United States die of lung cancer than of the next three causes of cancer-related death prostate cancer, breast cancer, and colorectal cancer combined (*Jamal et al., 2006*).

Between 1991 and 2002, the lung cancer incidence decreased 19.8% in men (1.8% reduction per year), but it increased 8% in women between 1990 and 1998 (1% increase per year) and subsequently decreased 2% between 1998 and 2002 (0.5% reduction per year). Lung cancer death rates for men have dropped by 19% during the past decade, whereas these rates continued to increase in women up to the year 2002 (*Ozols et al., 2007*).

Lung cancer is rapidly emerging as a major cause of mortality in the Middle East, Africa, and Asia as well. For instance, an estimated 71,228 annual cancer-related deaths will be attributed to lung cancer in Japan within 2 years (*Kaneko et al., 2003*).

The global rise in lung cancer incidence, together with the fact that the overall 5-year survival of patients with this disease is less than 15%, underscores the magnitude of the lung cancer epidemic (*Ferlay et al., 2006*).